

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

PerCP/Cyanine5.5 anti-human CD3

RRID:AB_2561628

Type: Antibody

Proper Citation

BioLegend Cat# 317336, RRID:AB_2561628

Antibody Information

URL: http://antibodyregistry.org/AB_2561628

Proper Citation: BioLegend Cat# 317336, RRID:AB_2561628

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2561628

Vendor: BioLegend

Catalog Number: 317336

Alternative Catalog Numbers: 317335

Record Creation Time: 20250820T063137+0000

Record Last Update: 20250821T002100+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang J, et al. (2026) EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. *Cell*.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Oh MS, et al. (2025) Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer. *Molecular cancer therapeutics*, 24(2), 286.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. *Cell*, 187(18), 4905.

Van der Meer JMR, et al. (2024) Generation of human ILC3 from allogeneic and autologous CD34+ hematopoietic progenitors toward adoptive transfer. *Cytherapy*, 26(2), 136.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Wang Y, et al. (2024) Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. *Cell reports. Medicine*, 5(6), 101580.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Tubridy EA, et al. (2024) CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival. *Gynecologic oncology*, 184, 74.

Gao Y, et al. (2024) Cross-tissue human fibroblast atlas reveals myofibroblast subtypes with distinct roles in immune modulation. *Cancer cell*, 42(10), 1764.

Liu H, et al. (2023) Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer cell*, 41(4), 693.

Eiva MA, et al. (2022) Systematic analysis of CD39, CD103, CD137, and PD-1 as biomarkers for naturally occurring tumor antigen-specific TILs. *European journal of immunology*, 52(1), 96.

Mudd PA, et al. (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. *Cell*, 185(4), 603.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(23), 5190.

Quiros-Fernandez I, et al. (2021) Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals. *EBioMedicine*, 72, 103610.

Hanna BS, et al. (2021) Interleukin-10 receptor signaling promotes the maintenance of a PD-1^{int} TCF-1⁺ CD8⁺ T cell population that sustains anti-tumor immunity. *Immunity*, 54(12), 2825.

Roider T, et al. (2021) Processing human lymph node samples for single-cell assays. *STAR protocols*, 2(4), 100914.

Kasper M, et al. (2021) Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis. *eLife*, 10.

Ott M, et al. (2020) Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. *JCI insight*, 5(17).

Wang J, et al. (2020) HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in Multiple Sclerosis. *Cell*, 183(5), 1264.